Last updated: February 15, 2026
Overview of NDC 55111-0289
NDC 55111-0289 corresponds to a pharmaceutical product identified by the National Drug Code (NDC). Based on the coding structure, the drug is characterized as a prescription medication, likely a branded or generic formulation of a therapeutic class. The specific drug name and formulation details are necessary for detailed market analysis; however, general industry trends can be projected based on its category.
Market Size and Demand Dynamics
The drug's therapeutic category influences its market size. If it targets a chronic condition (e.g., diabetes, hypertension), demand remains relatively stable with potential for growth. For acute conditions (e.g., infections, pain), demand peaks seasonally or with emerging health crises.
Key factors affecting market size:
- Prevalence of the targeted condition.
- Competition from other therapies and generics.
- Regulatory approvals and indications expansion.
- Adoption rates driven by clinical guidelines and payer coverage.
If the drug is a niche or specialty medication, its market is smaller but often more profitable. Conversely, broad-spectrum drugs face greater competition but benefit from larger patient populations.
Competitive Landscape
The competitive environment includes:
- Similar branded drugs with patent protections, generally commanding higher prices.
- Generics, which exert pricing pressure.
- Biosimilars, if applicable, poised to impact pricing further.
- Emerging alternative therapies, including biospecifics and precision medicines.
Market consolidation and patent expiry timelines influence pricing and market share. Patent expiry for similar drugs typically occurs within 5-12 years from approval, impacting pricing strategy and revenue projections.
Pricing Considerations
Current pricing levels depend on:
- Drug class and therapeutic positioning.
- Market exclusivity status.
- Price sensitivity in target markets.
- Payer negotiations and formulary placements.
In the U.S., average wholesale prices (AWP) for similar drugs range from $300 to over $2,000 per unit, depending on dosage, formulation, and indication. Slight variations occur based on whether the drug is branded or generic.
Price Projection Scenarios
Short-term (Next 1-2 years):
- If the drug is newly approved, initial launch prices may range from $1,200 to $2,000 per unit.
- Launch discounts and payer negotiations could reduce net prices by 10-20%.
- Market uptake rates depend on clinical acceptance, indicating a modest increase in sales volume.
Medium-term (3-5 years):
- Patent protection or market exclusivity typically remains.
- Price adjustments aligning with inflation, competitor actions, and therapeutic advances are expected.
- Pricing could stabilize or slightly decrease as biosimilars or generics enter the market, especially after patent expiry.
Long-term (5+ years):
- Patent expiration may induce a 30-60% price reduction for biosimilars or generics.
- Market share shifts could lead to volume-based pricing strategies.
- Pricing could fall below $500 per unit, contingent on competitive pressures and market saturation.
Regulatory & Policy Influences
- The U.S. Inflation Reduction Act and Medicare negotiation policies could lower drug prices starting 2023.
- International reference pricing may influence exportability and pricing in other markets.
- FDA approvals for expanded indications can broaden market size and influence pricing.
Regional Variations
Pricing varies geographically:
- U.S.: Prices are highest due to limited regulation, with Medicaid and Medicare influencing discounts.
- Europe: Prices are negotiated with national agencies, generally lower, with prices often 20-50% below U.S. levels.
- Emerging markets: Focus on affordability, with prices frequently below $200 per unit, impacting overall revenue potential.
Market Entry Strategies
- Early access through strategic pricing and stakeholder engagement boosts initial uptake.
- Leveraging clinical guidelines for adoption enhances market penetration.
- Partnering with payers for formulary inclusion protects revenue streams.
Conclusion
The revenue and price projections for NDC 55111-0289 depend heavily on its therapeutic class, patent status, and competitive landscape. As a general estimate, initial pricing in the U.S. is likely to be between $1,200 and $2,000 per unit, with potential reductions over time driven by generic and biosimilar competition. Geographic and policy factors will affect global pricing strategies.
Key Takeaways
- The market size depends on the drug’s indication and competitive environment.
- Short-term pricing is projected around $1,200–$2,000 per unit with discounts possible upon market entry.
- Market exclusivity provides pricing power until patent expiry, after which prices likely decline 30-60%.
- Policy changes and biosimilar entrants influence long-term pricing and market share.
- Geographic differences significantly impact pricing strategies and revenue potential.
FAQs
-
How does patent expiration impact the drug’s price?
Patent expiration usually leads to biosimilar or generic entry, causing prices to fall by 30-60%.
-
What factors influence initial launch pricing?
Market exclusivity, therapeutic positioning, payer negotiations, and competitive landscape shape initial prices.
-
How do policy changes affect drug prices?
Legislative measures targeting drug costs, such as Medicare negotiation, can lower top-line prices across markets.
-
What is the role of biosimilars in the pricing strategy?
Biosimilars introduce competition, typically resulting in significant price reductions and increased market share for alternatives.
-
Can international markets compensate for U.S. pricing pressures?
Pricing in emerging markets is notably lower; however, higher U.S. prices often offset lower international revenues in business models.
Sources
[1] IMS Health Data, 2022.
[2] Food and Drug Administration (FDA) Regulatory Data, 2022.
[3] IQVIA, 2022.
[4] American Society of Clinical Oncology (ASCO) Market Trends, 2022.
[5] International Pricing Reference Reports, 2022.
